Apologies for formatting, this is the document translated that...

Apologies for formatting, this is the document translated that Fes linked to:

SUBJECT: Purchase of an implantable synthetic dermal matrix for the reconstruction of complex wounds
Novosorb BTM (€ 8,985.60)

Given that the S.C. ASUGI Plastic Surgery Clinic required, in the programming of the
their annual needs for their institutional activities, among other things, the supply of the dermal matrix
double-layered resorbable implantable synthetic Novosorb BTM, from Australian manufacturer PolyNovo
Biomaterials Pty Limited, intended for the temporary treatment of skin lesions where the dermis has been
decimated or lost and to facilitate skin repair, indicated for burns and partial thickness wounds
or deep, reconstructive surgical wounds and injuries due to trauma, including in the case of tendons and bones exposed and for the
diabetic foot treatment;
having obtained with a note dated 04/27/2022 the favorable opinion of the purchase from the Management
Healthcare;
considering that the company Medival S.r.l., with registered office in Via San Crispino 33 - 35129 Padua (PD)
C.I./P.I. n. 01630000287 is the exclusive distributor throughout the Italian territory of the “NovoSorb
BTM "of PolyNovo Biomaterials Pty Limited, based at 2/320 Lorimer Street, Port Melbourne, Victoria, 3207,
Australia;
therefore considering that, pursuant to art. 36 c.2 letter a) of Legislative Decree 50/2016, we proceeded to
send the Request for Offer n. 34697/2022 for the purchase of
n. 12 Novosorb BTM implantable synthetic matrices for an estimated 12-month requirement to the Medival supplier
S.r.l .;
that upon the Request for Offer, the supplier Medival S.r.l. responded by proposing, among the available measures,
the Novosorb Btm item 10x10 cm at the unit price of Euro 720.00 + 4% VAT;
given that, on 05/25/2022, the supply was awarded to the company Medival S.r.l., for a
total of Euro 8,640.00 (excluding VAT), corresponding to the necessarily presumed needs for the period from
05/25/2022 to 05/24/2023;
found that, before proceeding with the purchase of the material in question, it was ascertained that it is not active
no agreement by MEPA-CONSIP, nor is a tender foreseen for the same object of supply from
part of the CUC Single Central Commission of the Friuli Venezia Giulia Region nor by ARCS;
noted that, as also results from the indications of ARCS, the procedures below Euro 40,000.00 over
VAT, and the procedures for the purchase of devices in industrial property are the responsibility of the individual companies
of the SSR, which also have no different indications from the regional CUC, and which therefore ASUGI has
title to conclude the award procedure;
considering that any subsequent awards by CONSIP and ARCS / CUC could
determine the early termination of the contract;
3
considered to identify Dr. Giovanni Maria Coloni as the sole responsible for the procedure,
Director of the S.C. Procurement and Service Management;
having regard to the "ASUGI Regulation for the award of" below threshold "contracts adopted with Decree no. 469
dated 19/05/2022 by the General Manager of the University Healthcare Company Giuliano Isontina;
having regard to the decree of the General Manager of ASUGI no. 1 dd. January 1, 2020;
The Director of the
S.C. PROCUREMENT AND SERVICE MANAGEMENT
determines
a) to have launched a procedure pursuant to art. 36 c. 2 letter a) of Legislative Decree 50/2016 for the supply of matrix
synthetic dermal implant for complex wound reconstruction Novosorb BTM for SC
Plastic surgery;
b) to purchase, for the reasons set out in the narrative of this deed, an implantable synthetic dermal matrix
for the reconstruction of complex wounds Novosorb BTM by the company Medival S.r.l with registered office in Via
San Crispino 33 - 35129 Padua (PD) C.I./P.I. n. 01630000287 - for an estimated total of € 8,985,600
(taxable € € 8,640.00 + 4% VAT equal to € 345.00) for the period from 25/05/2022 to 24/05/2023.
The total cost of € 8,985,600 (taxable € 8,640.00 + 4% VAT equal to € 345.00) will be charged to the
account 300.100.300.100 (Medical Devices) of the balance sheet of the Giuliano Isontina University Healthcare Company
for the exercises of competence.
Pursuant to art. 3 L. 136/10 and subsequent amendments (traceability of financial flows) the CIG is Y78365FE5E.
For the start of the supply referred to in this deed, it is not necessary to prepare the DUVRI pursuant to
of Legislative Decree 81/08 as amended by Legislative Decree 106/09, there is no risk of interference as the
devices / drugs are delivered directly to the Miscellaneous Warehouse / Pharmacy (located outside the
hospital area) and / or at the transit point, for subsequent delivery to the requesting departments by the staff
in charge.
This provision becomes enforceable from the date of publication on the company register
telematic.